Valuation: Veru Inc

Market Cap 42.8M 38.02M 35.49M 32.35M 61.01M 4.11B 61.58M 429M 166M 2.1B 161M 157M 6.75B P/E 2026 *
-2.89x
P/E 2027 * -2.74x
Enterprise Value 42.8M 38.02M 35.49M 32.35M 61.01M 4.11B 61.58M 429M 166M 2.1B 161M 157M 6.75B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.63%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 65 31/10/2016
Director of Finance/CFO 67 01/01/2013
Chief Tech/Sci/R&D Officer 64 01/04/2018
Director TitleAgeSince
Chairman 65 01/03/2018
Director/Board Member 68 01/10/2016
Director/Board Member 68 01/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
+1.39%+14.29% - - 42.8M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.06%-0.59%+52.63%+128.54% 43.39B
Weighted average by Cap. +0.12%-0.84%+56.96%+138.26%

Financials

2026 *2027 *
Net sales - -
Net income -23.3M -20.7M -19.32M -17.61M -33.21M -2.24B -33.52M -234M -90.61M -1.15B -87.48M -85.58M -3.67B -36.6M -32.52M -30.35M -27.66M -52.17M -3.52B -52.66M -367M -142M -1.8B -137M -134M -5.77B
Net Debt - -
Logo Veru Inc
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-